Published in Nat Rev Cardiol on January 12, 2010
Safety and Performance Evaluation of CircuLite Synergy | NCT00878527
Cardiogenic shock in ACS. Part 2: Role of mechanical circulatory support. Nat Rev Cardiol (2012) 1.08
Development of a Double-Lumen Cannula for a Percutaneous RVAD. ASAIO J (2015) 0.75
High fidelity computational simulation of thrombus formation in Thoratec HeartMate II continuous flow ventricular assist device. Sci Rep (2016) 0.75
Hemolysis and Pulmonary Insufficiency following Right Ventricular Assist Device Implantation. Case Rep Transplant (2012) 0.75
A Development of Nucleic Chromatin Measurements as a New Prognostic Marker for Severe Chronic Heart Failure. PLoS One (2016) 0.75
Repair of abdominal aortic aneurysm in heart transplant patients: before or after left ventricular assist device implantation? Thorac Cardiovasc Surg (2011) 0.75
Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation (2007) 22.81
Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med (2001) 18.91
PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell (2000) 10.25
Use of a continuous-flow device in patients awaiting heart transplantation. N Engl J Med (2007) 7.15
Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: implications for patient selection. Circulation (2007) 4.67
Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device. J Am Coll Cardiol (2009) 4.03
The effect of ventricular assist devices on post-transplant mortality an analysis of the United network for organ sharing thoracic registry. J Am Coll Cardiol (2009) 2.41
INTERMACS database for durable devices for circulatory support: first annual report. J Heart Lung Transplant (2008) 2.17
Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult heart transplant report--2007. J Heart Lung Transplant (2007) 2.03
Gastrointestinal bleeding rates in recipients of nonpulsatile and pulsatile left ventricular assist devices. J Thorac Cardiovasc Surg (2008) 1.71
Proof of concept: hemodynamic response to long-term partial ventricular support with the synergy pocket micro-pump. J Am Coll Cardiol (2009) 1.57
Improved mortality and rehabilitation of transplant candidates treated with a long-term implantable left ventricular assist system. Ann Surg (1995) 1.56
Severely impaired von Willebrand factor-dependent platelet aggregation in patients with a continuous-flow left ventricular assist device (HeartMate II). J Am Coll Cardiol (2009) 1.51
Left ventricular assist devices as destination therapy: a new look at survival. J Thorac Cardiovasc Surg (2005) 1.48
Improved mechanical reliability of the HeartMate XVE left ventricular assist system. Ann Thorac Surg (2006) 1.45
Improving outcomes with long-term "destination" therapy using left ventricular assist devices. J Thorac Cardiovasc Surg (2008) 1.39
First experiences with a novel magnetically suspended axial flow left ventricular assist device. Eur J Cardiothorac Surg (2004) 1.34
European experience of DuraHeart magnetically levitated centrifugal left ventricular assist system. Eur J Cardiothorac Surg (2009) 1.32
Left ventricular assist device support normalizes left and right ventricular beta-adrenergic pathway properties. J Am Coll Cardiol (2005) 1.13
Influence of inflow cannula length in axial-flow pumps on neurologic adverse event rate: results from a multi-center analysis. J Heart Lung Transplant (2008) 1.06
In vivo evaluation of the HeartWare centrifugal ventricular assist device. Tex Heart Inst J (2007) 1.04
First clinical experience with the Incor left ventricular assist device. J Heart Lung Transplant (2005) 1.03
VentrAssist left ventricular assist device: clinical trial results and Clinical Development Plan update. Eur J Cardiothorac Surg (2007) 0.99
The cost of long-term LVAD implantation. Ann Thorac Surg (2001) 0.96
First human use of partial left ventricular heart support with the Circulite synergy micro-pump as a bridge to cardiac transplantation. Eur Heart J (2008) 0.94
Mechanical device-based methods of managing and treating heart failure. Circulation (2005) 0.91
Cost-effectiveness of ventricular assist device use in the United Kingdom: results from the evaluation of ventricular assist device programme in the UK (EVAD-UK). J Heart Lung Transplant (2006) 0.91
The DuraHeart VAD, a magnetically levitated centrifugal pump: the University of Vienna bridge-to-transplant experience. Circ J (2006) 0.91
HeartWare miniature axial-flow ventricular assist device: design and initial feasibility test. Tex Heart Inst J (2009) 0.90
Evaluation for a ventricular assist device: selecting the appropriate candidate. Circulation (2009) 0.90
Cost-effectiveness of left ventricular-assist devices in end-stage heart failure. Expert Rev Cardiovasc Ther (2008) 0.89
Continuous-flow rotary left ventricular assist devices with "3rd generation" design. Semin Thorac Cardiovasc Surg (2008) 0.89
High mortality without ESCAPE: the registry of heart failure patients receiving pulmonary artery catheters without randomization. J Card Fail (2008) 0.86
Hemodynamic and physiologic changes during support with an implantable left ventricular assist device. J Thorac Cardiovasc Surg (1995) 0.86
Initial clinical experience with the VentrAssist left ventricular assist device: the pilot trial. J Heart Lung Transplant (2008) 0.84
First human implantation of a new rotary blood pump: design of the clinical feasibility study. Hellenic J Cardiol (2007) 0.83
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med (2005) 15.46
Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail (2013) 4.98
Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA (2007) 4.30
Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction. JAMA (2008) 3.31
Results of the post-U.S. Food and Drug Administration-approval study with a continuous flow left ventricular assist device as a bridge to heart transplantation: a prospective study using the INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support). J Am Coll Cardiol (2011) 3.06
Acute heart failure syndromes: current state and framework for future research. Circulation (2005) 2.47
The effect of ventricular assist devices on post-transplant mortality an analysis of the United network for organ sharing thoracic registry. J Am Coll Cardiol (2009) 2.41
Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program. J Am Coll Cardiol (2008) 2.35
Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation (2002) 2.20
Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. J Am Coll Cardiol (2007) 1.94
Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach. J Am Coll Cardiol (2010) 1.93
Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial. Eur Heart J (2011) 1.88
Identifying patients hospitalized with heart failure at risk for unfavorable future quality of life. Circ Cardiovasc Qual Outcomes (2011) 1.88
Aligning quality and payment for heart failure care: defining the challenges. J Card Fail (2003) 1.71
Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol (2003) 1.67
Relationship between clinical trial site enrollment with participant characteristics, protocol completion, and outcomes: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) trial. J Am Coll Cardiol (2012) 1.64
Ventricular assist device therapy normalizes inducible nitric oxide synthase expression and reduces cardiomyocyte apoptosis in the failing human heart. J Am Coll Cardiol (2005) 1.61
Acute detection of ST-elevation myocardial infarction missed on standard 12-Lead ECG with a novel 80-lead real-time digital body surface map: primary results from the multicenter OCCULT MI trial. Ann Emerg Med (2009) 1.60
Key issues in end point selection for heart failure trials: composite end points. J Card Fail (2005) 1.49
Enalapril treatment and hospitalization with atrial tachyarrhythmias in patients with left ventricular dysfunction. Am Heart J (2004) 1.47
Effects of tolvaptan on dyspnoea relief from the EVEREST trials. Eur Heart J (2009) 1.47
Reversal of left ventricular remodeling by pericardial tamponade. J Card Fail (2005) 1.45
Outcomes in patients with symptomatic cerebrovascular disease undergoing heart transplantation. J Am Coll Cardiol (2011) 1.42
Predicting adverse events during angiotensin receptor blocker treatment in heart failure: results from the HEAAL trial. Eur J Heart Fail (2012) 1.40
Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). J Card Fail (2005) 1.39
Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit (2006) 1.30
Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial. Eur Heart J (2013) 1.30
Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction. J Am Coll Cardiol (2004) 1.28
Clinical trials of pharmacological therapies in acute heart failure syndromes: lessons learned and directions forward. Circ Heart Fail (2010) 1.27
Vasopressin v(2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia. Am J Cardiol (2006) 1.23
Ventricular remodeling in heart failure: a credible surrogate endpoint. J Card Fail (2003) 1.21
Research priorities in hypertrophic cardiomyopathy: report of a Working Group of the National Heart, Lung, and Blood Institute. Circulation (2010) 1.18
The problem of decompensated heart failure: nomenclature, classification, and risk stratification. Am Heart J (2003) 1.16
Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction. Circ Heart Fail (2010) 1.15
Randomized, controlled evaluation of short- and long-term benefits of heart failure disease management within a diverse provider network: the SPAN-CHF trial. Circulation (2004) 1.14
Clinical course and predictive value of liver function tests in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST trial. Eur J Heart Fail (2012) 1.11
Effects of angiotensin II receptor blockade versus angiotensin-converting-enzyme inhibition on ventricular remodelling following myocardial infarction in the mouse. Clin Sci (Lond) (2003) 1.09
Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial. J Am Coll Cardiol (2008) 1.05
Critical elements of clinical follow-up after hospital discharge for heart failure: insights from the EVEREST trial. Eur J Heart Fail (2010) 1.04
Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan. J Card Fail (2013) 1.02
Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. Eur J Heart Fail (2013) 1.00
Gender-specific patterns of left ventricular and myocyte remodeling following myocardial infarction in mice deficient in the angiotensin II type 1a receptor. Am J Physiol Heart Circ Physiol (2005) 0.99
Relation between left ventricular remodeling and clinical outcomes in heart failure patients with left ventricular systolic dysfunction. J Card Fail (2002) 0.99
The impact of chronic obstructive pulmonary disease in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST Trial. J Card Fail (2012) 0.98
Phase III clinical trial end points in acute heart failure syndromes: a virtual roundtable with the Acute Heart Failure Syndromes International Working Group. Am Heart J (2009) 0.98
Persistence of cardiovascular risk after rofecoxib discontinuation. Arch Intern Med (2010) 0.98
Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. Circ Heart Fail (2012) 0.97
Effects of a percutaneous mechanical circulatory support device for medically refractory right ventricular failure. J Heart Lung Transplant (2011) 0.97
American Heart Association atrial fibrillation research summit: a conference report from the American Heart Association. Circulation (2011) 0.97
Acute heart failure syndromes in patients with coronary artery disease early assessment and treatment. J Am Coll Cardiol (2009) 0.95
A multicenter randomized controlled evaluation of automated home monitoring and telephonic disease management in patients recently hospitalized for congestive heart failure: the SPAN-CHF II trial. J Card Fail (2010) 0.95
Hypoalbuminaemia and incident heart failure in older adults. Eur J Heart Fail (2011) 0.93
Predictive value of low relative lymphocyte count in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. Circ Heart Fail (2012) 0.92
Management of HeartWare left ventricular assist device thrombosis using intracavitary thrombolytics. J Thorac Cardiovasc Surg (2011) 0.92
Should beta-blockers be given to patients with heart disease and peanut-induced anaphylaxis? A decision analysis. J Allergy Clin Immunol (2004) 0.91
"Systolic and diastolic dysfunction" in heart failure? Time for a new paradigm. J Card Fail (2003) 0.91
Arginine vasopressin antagonists for the treatment of heart failure and hyponatremia. Circulation (2008) 0.91
Natriuretic peptides and cardiovascular events: more than a stretch. JAMA (2007) 0.90
Serum aldosterone is associated with mortality and re-hospitalization in patients with reduced ejection fraction hospitalized for acute heart failure: analysis from the EVEREST trial. Eur J Heart Fail (2013) 0.90
Noninvasive assessment of left ventricular remodeling: concepts, techniques, and implications for clinical trials. J Card Fail (2002) 0.90
Influence of donor cocaine use on outcome after cardiac transplantation: analysis of the United Network for Organ Sharing Thoracic Registry. J Heart Lung Transplant (2008) 0.90
Weight changes after hospitalization for worsening heart failure and subsequent re-hospitalization and mortality in the EVEREST trial. Eur Heart J (2009) 0.90
Inappropriate implantable cardioverter-defibrillator therapy due to electromagnetic interference in patient with a HeartWare HVAD left ventricular assist device. Heart Rhythm (2010) 0.88
Reliability of ventricular remodeling as a surrogate for use in conjunction with clinical outcomes in heart failure. Am J Cardiol (2005) 0.88
New concepts in post-infarction ventricular remodeling. Rev Cardiovasc Med (2003) 0.87
Prognostic significance of serum total cholesterol and triglyceride levels in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial). Am J Cardiol (2012) 0.85
Implantable cardioverter-defibrillators in patients hospitalized for heart failure with chronically reduced left ventricular ejection fraction. Am J Ther (2010) 0.84
Evaluation of myocardial mechanics with three-dimensional speckle tracking echocardiography in heart transplant recipients: comparison with two-dimensional speckle tracking and relationship with clinical variables. Eur Heart J Cardiovasc Imaging (2013) 0.84
Fatty infiltration of right ventricle (adipositas cordis): an unrecognized cause of early graft failure after cardiac transplantation. J Heart Lung Transplant (2005) 0.84
Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment. J Cardiovasc Med (Hagerstown) (2012) 0.84
Right ventricular dysfunction in chronic dilated cardiomyopathy and heart failure. Coron Artery Dis (2005) 0.84
Health-related quality of life in a multicenter randomized controlled comparison of telephonic disease management and automated home monitoring in patients recently hospitalized with heart failure: SPAN-CHF II trial. J Card Fail (2011) 0.83
Haemodynamic effects, safety, and pharmacokinetics of human stresscopin in heart failure with reduced ejection fraction. Eur J Heart Fail (2013) 0.82
Eptifibatide for the treatment of HeartMate II left ventricular assist device thrombosis. Circ Heart Fail (2012) 0.82
Heart failure disease management a sustainable energy source for the health care engine. J Am Coll Cardiol (2010) 0.82
Peripheral vascular endothelial function correlates with exercise capacity in cardiac transplant recipients. Am J Cardiol (2003) 0.81
Hospital cost effect of a heart failure disease management program: the Specialized Primary and Networked Care in Heart Failure (SPAN-CHF) trial. Am Heart J (2006) 0.81
Recent advances in the treatment of heart failure. Circ J (2002) 0.81
Bivalirudin for treatment of LVAD thrombosis: a case series. ASAIO J (2014) 0.80
Pharmacokinetic monitoring of mycophenolic acid in heart transplant patients: correlation the side-effects and rejections with pharmacokinetic parameters. Ann Transplant (2012) 0.80
Colloid osmotic pressure: an under-recognized factor in the clinical syndrome of heart failure. J Am Coll Cardiol (2003) 0.80
Comparison of survival and other complications after heart transplantation in patients taking amiodarone before surgery versus those not taking amiodarone. Am J Cardiol (2004) 0.80
Prognostic value of monocyte count in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial). Am J Cardiol (2012) 0.80
Atrial fibrillation or flutter on initial electrocardiogram is associated with worse outcomes in patients admitted for worsening heart failure with reduced ejection fraction: findings from the EVEREST Trial. Am Heart J (2012) 0.80
Ventricular remodeling fundamental to the progression (and regression) of heart failure. J Am Coll Cardiol (2011) 0.80